Clinical Trial Update: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating EVP-6124 as an adjunct pro-cognitive treatment in schizophrenia patients on stable antipsychotic therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• EVP-6124

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Schizophrenia, Impaired Cognition | Phase 3 | Status: COMPLETED